<DOC>
	<DOCNO>NCT02168491</DOCNO>
	<brief_summary>Premixed insulin-based therapy standard insulin treatment strategy Austria . The widespread use premixed insulin explain high acceptance health care professional patient due one single product flexible number injection ( 1-3 daily ) cover demand control fasting postprandial glucose excursion patient diabetes . However , use pre-mixed insulin frequently lead high insulin demand consequently weight gain increase risk hypoglycemia . Hence , achieve good metabolic control patient remain major challenge . For patient , approach treatment intensification without face typical risk insulin treatment ( hypoglycemia weight increase ) major importance . One , far exploit option may BIT-strategy : Basal insulin combination incretin-based therapy . Pathophysiologically basal insulin inhibits glucose production liver , decrease hepatic insulin resistance improve function beta cell postprandial state discharge fast insulin secretion . During diabetes progression steadily increase HbA1c level - despite good fasting blood glucose control - indicate need additional intervention meal-related glucose excursion . In stage type-2 diabetes basal insulin combine prandial ( short-acting ) insulin prandial GLP-1 receptor agonist . However , regard important safety parameter : risk hypoglycemia weight gain long-term treatment GLP-1 receptor agonists beneficial . Lixisenatide novel GLP-1 receptor agonist pronounce postprandial ( PPG ) effect fit basal insulin mode action primarily focus fast blood glucose reduction . Therefore 10 patient ( gender ) treatment premixed insulin ( 2-3 time daily ) HbA1c &gt; 7 % switch basal insulin glargine ( Lantus , daily ) GLP-1 receptor agonist Lixisenatide ( Lyxumia , daily ) . The investigator hypothesize switch therapy base premixed insulin simple , daily administer combination basal insulin plus GLP-1 receptor agonist patient type-2 diabetes achieve therapeutic target ( HbA1c &gt; 7 % ) clinically feasable patient set</brief_summary>
	<brief_title>Feasibility Once/Daily Administered GLP/1 Receptoragonist ( Lixisenatide ) Combination With Basal Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Age 18 70a Subjects understand study related activity give write informed concent HbA1c 7 10 % treatment premixed insulin ( 23 injection ) Females childbearing age History hypoglycemia unawareness Gastrointestinal disease associate prolonged nausea vomit Impaired liver function ( transaminase &gt; 2x normal ) Impaired kidney function ( creatinin &gt; 1,2 mg/dl ) Known intolerance GLP1 receptor agonists History pancreatitis pancreas tumor Malignancies , autoimmune disease Severe dyslipidemia ( serum triglyceride &gt; 400 mg/dl , cholesterol &gt; 300 mg/dl ) Psychiatric disorder Oral glucose lower medication except metformin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>